IHL

cover
Incannex and Monash University joined forces to conduct world first psilocybin psychedelic medicine clinical trial for potentialin patients with Generalised Anxiety Disorder Treatment

Clinical Stage pharmaceutical development company Incannex Healthcare Limited (ASX: IHL) has announced a partnership agreement with Monash University to conduct a Phase 2 randomised double-blind active-placebo-controlled trial to assess the safety and efficacy of psilocybin-assisted psychotherapy in the treatment of Generalised Anxiety Disorder (‘GAD’).

cover
研究证据表明IHL-675A候选药的抗炎特性比单用大麻二酚更强

临床阶段药物开发商Incannex Healthcare(ASX:IHL)宣布,其大麻素候选药物IHL-675的关键成分在体外临床前研究中显示出强大的协同活性,可强力抑制炎症。该候选药物可能是败血症相关急性呼吸窘迫综合征(SAARDS)的潜在治疗方法,该病是新冠病毒的死亡主因。